An American peptide company
that can prove what's in the vial.

What we do

Nortian Peptide Sciences is a specialty peptide company built by Nortian Group. We own licensed 503A pharmacies that compound prescriptions to order, and we release every batch against a documented panel for identity, purity, potency, sterility and particulates.

Peptides sit between small molecules and biologics: short amino-acid chains with the specificity of a biologic and the manufacturability of a small molecule. The category has grown far faster than its quality infrastructure, and that gap is the reason this company exists.

Why it matters

Independent testing of gray-market peptides has found purity anywhere from 5% to 75% of what the label claimed, along with heavy metals above injectable limits, mislabeled sequences and no sterility testing at all. Roughly 55% of demand in this category sits in illegal channels.

Our answer is not a louder claim. It is a lot number you can look up.

Where we are today

We own and operate the pharmacies, and we test every batch. Our own API synthesis plants in Missouri come online in 2028 and 2029 — Springfield first, then St. Joseph. Until then the active ingredient comes from Tier-1 U.S. and allied producers and is tested on arrival.

We are deliberate about that distinction. “We make the molecule” is a 2028 sentence, and writing it in the present tense today would turn our best differentiator into our biggest liability.

Our operating sponsor

Nortian Group, our operating sponsor, already runs a 160,000 sq ft peptide facility in Springfield, Missouri.

That facility produces hydrolyzed bovine collagen peptides, a different product from the synthetic clinical peptides dispensed here. We name it as evidence the group can build and run a plant, not as the source of any preparation on this site.

What we will not do

• Publish a clinical claim we cannot trace to a source.
• Present a fictional person as a real patient or provider.
• Copy a competitor’s shipping promise and call it ours.
• Describe a plant that opens in 2028 as though it were running today.